[177Lu]Lu-TST001
/ Transcenta
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 13, 2023
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
(PRNewswire)
- "Transcenta Holding Limited...announces that the preclinical anti-tumor efficacy and safety results of [177Lu]Lu-TST001 have been published on European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI). In this preclinical studies, [177Lu]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including gastric cancer."
Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1